HB 2110 requires, for the next State Employee Health Plan (SEHP) coverage year (Plan Year 2023), the State Employees Health Care Commission to provide coverage for the diagnosis and prescribed treatment for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), for the purposes of studying the utilization and cost of such coverage. The bill requires the Commission, pursuant to the “test track” or pilot program requirements in the Insurance Code (KSA 40-2249a), to submit a report to the President of the Senate and the Speaker of the House of Representatives on or before March 1, 2024, which includes the following information pertaining to the mandated coverage for PANS and PANDAS provided during Plan Year 2023: ● The impact the mandated coverage for PANS and PANDAS required by the bill has had on the SEHP; ● Data on the utilization of coverage for PANS and PANDAS by covered individuals and the cost of providing such coverage; and ● A recommendation whether such mandated coverage should continue in the SEHP or whether additional utilization and cost data is required.